A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 May 2018
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics
- Sponsors TesoRx
- 21 May 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2017 According to a TesoRx Pharma media release, enrollment will include at least 10 evaluable native Japanese subjects intended to contribute towards TSX-011 regulatory approval efforts in Japan. Top-line results from this trial are expected in the second half of 2018.
- 20 Nov 2017 Status changed from not yet recruiting to recruiting.